REFERENCES
- Hardy KH, Rosevear JW, Sams WM Jr, et al: Scleroderma and urinary excretion of acidic glycosaminoglycans. Mayo Clin Proc 46: 119–127, Feb 1971
- Laskin DM, Engel MB, Joseph NR, et al: A test of connective tissue state and reactivity in collagen diseases. J Clin Invest 40: 2153–2161, 1961
- Fleischmajer R, Lara JV, Krol S: Localized scleroderma: A histochemical and chemical study. Arch Dermatol 94: 531–535, 1966
- LeRoy EC: Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. (Abstr) Arthritis Rheum 15: 116, 1972
- Scudamore HH, Hoffman HN II, Green PH: Scleroderma (systemic sclerosis) of the small intestine: Evaluation of intestinal absorption, pancreatic function and therapy with pancreatic extract or antibiotics. (Abstr) Gastroenterology 48: 847, 1965
- Medsger TA Jr, Masi AT, Rodnan GP, et al: Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75: 369–376, 1971
- Rothfield NF, Rodnan GP: Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma). Arthritis Rheum 11: 607–617, 1968
- Rowell NR, Beck JS: The diagnostic value of an antinuclear antibody test in clinical dermatology. Arch Dermatol 96: 290–295, 1967
- Fennell RH Jr, Rodnan GP, Vasquez JJ: Variability of tissue-localizing properties of serum from patients with different disease states. Lab Invest 2: 24–31, 1962
- Beck JS, Anderson JR, Gray RG, et al: Antinuclear and precipitating autoantibodies in progressive systemic sclerosis. Lancet 2: 1188–1190, 1963
- Seligmann M, Cannat A, Hamard M: Studies on antinuclear antibodies. Ann NY Acad Sci 124: 816–832, 1965
- Burnham TK, Fine G, Neblett TR: The immuno-fluorescent tumor imprint technique. II. The frequency of antinuclear factors in connective tissue diseases and dermatoses. Ann Intern Med 65: 9–19, 1966
- Ritchie RF: Antinucleolar antibodies. Their frequency and diagnostic association. N Engl J Med 282: 1174–1178, 1970
- Jordan RE, Deheer D, Schroeter A, et al: Antinuclear antibodies: Their significance in scleroderma. Mayo Clin Proc 46: 111–113, 1971
- Tan EM: Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus. J Lab Clin Med 70: 800–812, Nov 1967
- Muramatsu M, Busch H: Studies on nucleolar RNA of the Walker 256 carcinosarcoma and the liver of the rat. Cancer Res 24:1028–1034, 1964
- Willerson JT, Thompson RH, Hookman P, et al: Reserpine in Raynaud's disease and phenomenon: Short-term response to intra-arterial injection. Ann Intern Med 72: 17–27, 1970
- Abboud FM, Eckstein JW, Lawrence MS, et al: Preliminary observations on the use of intra-arterial reserpine in Raynaud's phenomenon. Circulation, Suppl 2, 36: 49, 1967
- Romeo SG, Whalen RE, Tindall JP: Intra-arterial administration of reserpine. Its use in patients with Raynaud's disease or Raynaud's phenomenon. Arch Intern Med 125: 825–829, 1970
- Varadi DP, Lawrence AM: Suppression of Raynaud's phenomenon by methyldopa. Arch Intern Med 124: 13–18, 1969
- Kontos HA, Wasserman JA: Effect of reserpine in Raynaud's phenomenon. Circulation 39: 259–266, 1969
- Pan SF, Rodnan GP, Wald N: Chromosomal abnormalities in progressive systemic sclerosis (scleroderma). (Abstr) Arthritis Rheum 14:407–408, 1971
- Bloom BR, Glade PR: In-Vitro Methods in Cell Mediated Immunity. New York, Academic Press Inc, 1971